The corresponding results revealed that using the selective inhibitor of ADAM17 (JG26) and the selective inhibitor of ADAM10 (GI254023X) to treat EMT-CRC exosome-treated cells did not reverse the VE-cadherin internalization and enhanced barrier permeability induced by EMT-CRC exosomes in vascular endothelial cells. Here, CDH5 is linked to colorectal carcinoma.